Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sierra Oncology Inc (SRRA)

Sierra Oncology Inc (SRRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,342,801
  • Shares Outstanding, K 24,419
  • Annual Sales, $ 0 K
  • Annual Income, $ -94,660 K
  • 60-Month Beta 0.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.13
Trade SRRA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.77
  • Most Recent Earnings $-1.33 on 05/06/22
  • Latest Earnings Date 08/04/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.95
  • Number of Estimates 2
  • High Estimate -0.88
  • Low Estimate -1.02
  • Prior Year -1.67
  • Growth Rate Est. (year over year) +43.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.58 +0.74%
on 05/31/22
55.19 -0.36%
on 06/24/22
+0.21 (+0.38%)
since 05/27/22
3-Month
30.87 +78.12%
on 03/31/22
55.19 -0.36%
on 06/24/22
+22.61 (+69.83%)
since 03/30/22
52-Week
14.91 +268.81%
on 01/24/22
55.19 -0.36%
on 06/24/22
+35.52 (+182.43%)
since 06/30/21

Most Recent Stories

More News
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application...

SRRA : 54.99 (+0.04%)
GSK Receives Regulatory Nod for Consumer Healthcare Demerger

GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.

GSK : 42.87 (-0.28%)
UL : 50.19 (+0.10%)
PFE : 27.75 (-0.11%)
SRRA : 54.99 (+0.04%)
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the...

SRRA : 54.99 (+0.04%)
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the...

SRRA : 54.99 (+0.04%)
Sierra Oncology Reports First Quarter 2022 Results

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results...

SRRA : 54.99 (+0.04%)
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the...

SRRA : 54.99 (+0.04%)
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline...

SRRA : 54.99 (+0.04%)
GSK : 42.87 (-0.28%)
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA

Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will...

SRRA : 54.99 (+0.04%)
GSK : 42.87 (-0.28%)
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline...

SRRA : 54.99 (+0.04%)
GSK : 42.87 (-0.28%)
RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned...

SRRA : 54.99 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central...

See More

Key Turning Points

3rd Resistance Point 55.30
2nd Resistance Point 55.24
1st Resistance Point 55.11
Last Price 54.99
1st Support Level 54.92
2nd Support Level 54.86
3rd Support Level 54.73

See More

52-Week High 55.19
Last Price 54.99
Fibonacci 61.8% 39.80
Fibonacci 50% 35.05
Fibonacci 38.2% 30.30
52-Week Low 14.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar